title: Population-based p16 and HPV positivity rates in oropharyngeal cancer in Southeast Scotland.
abstract: We assessed a population-based cohort of patients diagnosed with oropharyngeal squamous cell carcinoma in Southeast Scotland over 13 months. p16 and human papilloma virus (HPV) expression were determined, and correlated with stage, treatment, smoking and alcohol history, and disease outcomes. Retrospective analysis was performed on 60 patients. p16 immunohistochemistry and HPV genotyping were performed on formalin-fixed paraffin-embedded tissues. HPV infection (as defined by p16 positivity and/or HPV PCR positivity) was identified in 57% of samples, while dual positives were detected in 45% of cases. HPV16 was most prevalent of the HPV types and was associated with 90% of positive samples. Cause-specific 1-year and 2-year survivals were 82.5% and 78.2%, respectively. The p16-positive and HPV-positive groups demonstrated significantly increased cause-specific survival in comparison with their negative counterparts.
authors.affiliation: Department of Oncology, Western General Hospital, Edinburgh, UK.
authors.forename: L A R
authors.initials: LA
authors.lastname: Wells
authors.affiliation: Department of Oncology, Western General Hospital, Edinburgh, UK.
authors.forename: E J
authors.initials: EJ
authors.lastname: Junor
authors.affiliation: Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, UK.
authors.forename: B
authors.initials: B
authors.lastname: Conn
authors.affiliation: Scottish Reference HPV Laboratory, Royal Infirmary of Edinburgh, Edinburgh, UK.
authors.forename: S
authors.initials: S
authors.lastname: Pattle
authors.affiliation: Scottish Reference HPV Laboratory, Royal Infirmary of Edinburgh, Edinburgh, UK.
authors.forename: K
authors.initials: K
authors.lastname: Cuschieri
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology / Q000628:therapy / Q000821:virology; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis*; D004279:DNA, Viral / Q000235:genetics; D005260:Female; D061809:Human Papillomavirus DNA Tests; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009959:Oropharyngeal Neoplasms / Q000737:chemistry / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology / Q000628:therapy / Q000821:virology; D027383:Papillomaviridae / Q000235:genetics*; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy / Q000821:virology; D011237:Predictive Value of Tests; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D012606:Scotland / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16; D004279:DNA, Viral
keywords: HEAD AND NECK CANCER; HPV; IMMUNOHISTOCHEMISTRY; PAPILLOMA VIRUSES